We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 27, 2021

Safety and Efficacy of Nivolumab + Ipilimumab in Patients With Melanoma and Brain Metastases



Additional Info

Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204)
Neuro-oncology 2021 Apr 21;[EPub Ahead of Print], HA Tawbi, PA Forsyth, FS Hodi, CD Lao, SJ Moschos, O Hamid, MB Atkins, K Lewis, RP Thomas, JA Glaspy, S Jang, AP Algazi, NI Khushalani, MA Postow, AC Pavlick, MS Ernstoff, DA Reardon, I Puzanov, RR Kudchadkar, AA Tarhini, A Sumbul, JI Rizzo, KA Margolin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading